Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort Scientific Corporation and Wright Medical Group, Inc. Enter Into Definitive Agreement Under Which MicroPort Will Acquire Wright's OrthoRecon Business


Transaction Enables MicroPort to Become Global Medical Device Company with Recognized Orthopedic Franchise to Commercialize in Rapidly Growing China Orthopedic Market

Purchase Price of $290 Million in Cash

SHANGHAI, China – June 25, 2013 – MicroPort Scientific Corporation (HK: 0853) and Wright Medical Group, Inc. (NASDAQ: WMGI) entered into a definitive agreement on June 18, 2013 under which MicroPort Medical B.V., a subsidiary of MicroPort Scientific Corporation, will acquire Wright's OrthoRecon business. The purchase price is $290 million and is payable in cash at closing, which is expected to occur by the end of the third quarter or during the fourth quarter of 2013.
Wright's OrthoRecon business includes hip and knee implant products and generated global revenue of approximately $269 million in 2012. The OrthoRecon business has established hip and knee franchise brands including DYNASTY® and CONSERVE® hips, PROFEMUR® modular stems, SUPERPATH™ minimally invasive hip surgical instrumentation, and ADVANCE® and EVOLUTION® medial-pivot knee implants. According to industry research, the worldwide hip and knee reconstruction market was approximately $14 billion in 2012. In addition, the China hip and knee implant market is estimated to be approximately $1.3 billion by 2018 and is growing at approximately 17% per year.
Mr. Hongbin Sun, Chief Financial Officer of MicroPort Scientific Corporation and the Executive Director of the MicroPort Orthopedic business stated, "The acquisition of Wright's OrthoRecon business will enable us to significantly expand our orthopedic business from both product and geographic perspectives. It will be highly complementary to our existing spine and trauma platforms. Wright Medical's new generation EVOLUTION® Medial-Pivot Knee product is recognized as a best-in-class product globally, with a design that is considered by some physicians as being anatomically very suitable for Asian patients. Its SUPERPATH™ minimally invasive hip replacement instruments are a dedicated minimally invasive surgical product requiring only a small open wound and significantly reducing patient recovery time. Wright Medical's OrthoRecon business will become an important addition from which our orthopedic business can continue to grow."
Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort Scientific Corporation commented, "This acquisition will be a key milestone in the development of MicroPort's orthopedic business, and will become an important stepping stone in MicroPort's global development strategy. We recognize that Wright's OrthoRecon business has a unique and important position in the global orthopedic industry, and throughout its 60+ year history, has served the medical community well with various innovative products. We look forward to adding Wright's portfolio of high-quality, clinically proven hip and knee products and welcoming their talented OrthoRecon team to our organization to support our continued expansion into fast-growing Asian markets and elsewhere around the world. We are eager to working closely with the existing OrthoRecon management, employees and stakeholders to substantially grow the OrthoRecon business and gear it up to a higher level. With this acquisition as well as through continued organic growth, MicroPort is becoming a true global enterprise with bases in China, USA, Europe and elsewhere in the world to serve a much larger patient populations with high quality and innovative medical products that are affordable to all."
Mr. Robert Palmisano, President and Chief Executive Officer of Wright Medical, stated, "We are pleased we have found an excellent strategic buyer in MicroPort, a company that is deeply committed to the success of the OrthoRecon business and will continue to provide the focus and investment to enable it to reach its full potential. Also, very importantly, this will provide our OrthoRecon employees with opportunities for career growth and development. We are grateful to our OrthoRecon employees for their dedication and hard work, and we look forward to working with MicroPort to ensure a seamless transfer and the continued success of the OrthoRecon business as part of MicroPort."
Post close, MicroPort's global orthopedic business will be headquartered in current OrthoRecon location in Arlington, Tennessee, United States.
The transaction is subject to customary closing conditions, including MicroPort shareholder approval and receipt of regulatory clearances. The transaction received the approval of the board of directors of both MicroPort and Wright. In addition, voting undertakings have been given by shareholders of MicroPort holding greater than the required voting shares needed to approve the transaction.
In connection with this transaction, BofA Merrill Lynch and Morrison & Foerster LLP advised MicroPort Scientific Corporation.


About Wright Medical
Wright Medical Group, Inc. is a global orthopedic company that that provides solutions that enable clinicians to alleviate pain and restore their patients' lifestyles. The company is the recognized leader of surgical solutions for the foot and ankle market and markets its products in over 60 countries worldwide.
For more information, please refer to:

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957


[Prev]:The Annual General Meeting of MicroPort Scientific Corporation 2013 Held in Shanghai
[Next]:Disposable Cervical Dilator Received SFDA Product Certificate